Dr. Reddy's Laboratories Limited — Q4 FY25 earnings call

Call held 9 May 2025

Management summary

Dr. Reddy's delivered a milestone FY25 with record revenues and the first-ever $1 billion EBITDA achievement. The company demonstrated strong operational performance with significant growth in both revenue and profitability, supported by strategic acquisitions and continued investment in R&D capabilities across diverse therapeutic areas.

Highlights

  • Record high revenues exceeding $3.8 billion for full year FY25

  • EBITDA crossed $1 billion threshold for the first time with 11% YoY growth

  • Q4 revenues of ₹8,506 crores ($996 million) with 20% YoY growth

  • Q4 EBITDA of ₹2,475 crores ($290 million) with 32% YoY growth

  • Successful acquisition and integration of NRT business contributing ₹1,202 crores annually

  • Strong R&D investment of ₹2,738 crores ($320 million) for full year, up 20% YoY

  • Consolidated gross margin stable at 58.5% for full year

  • PBT of ₹2,005 crores ($235 million) in Q4 with 25% YoY growth

Key financials

2 periods

Headline

  • Full Year Revenue
    ₹32,554 Cr
    YoY +17%
  • Full Year EBITDA
    ₹9,213 Cr
    YoY +11%
  • Full Year Gross Margin
    58.5%
    YoY 0%
  • Full Year R&D Investment
    ₹2,738 Cr
    YoY +20%

Q4

  • Revenue
    ₹8,506 Cr
    YoY +20%
  • EBITDA
    ₹2,475 Cr
    YoY +32%
  • Gross Margin
    55.6%
    YoY -3%
  • PBT
    ₹2,005 Cr
    YoY +25%

What they filed

Q4 FY26: revenue down 11.5%, net profit down 86.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue7,696 8,038 8,381 8,528 8,572 +11%8,828 +10%8,753 +4%7,546 −12%
EBITDA2,130 2,076 2,273 1,998 2,174 +2%2,010 −3%1,888 −17%382 −81%
Net profit1,392 1,342 1,404 1,587 1,410 +1%1,337 −0%1,190 −15%221 −86%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • ₹0 Cr Revenue
  • ₹0 Cr Revenue
  • ₹1,202 Cr Revenue

Guidance & targets

R&D Investment

  • Research and Development focus R&D Investment · Ongoing · High confidence Differentiated pipeline across small molecules, biosimilars, complex generics, peptides and novel oncology
    The investment was largely focused on building a differentiated pipeline, spanning small molecules, biosimilars, complex generics, including peptides and novel oncology assets

    — M. V. Narasimham

Tax Rate

  • Effective Tax Rate expectation Tax Rate · Going forward · Medium confidence Normal ETR range
    We expect the ETR for

    — M. V. Narasimham

Risks & concerns

  • Gross margin pressure in Q4

    medium

    Q4 gross margins declined 300 bps YoY to 55.6% due to reduced manufacturing overhead leverage and higher milestone income in comparative period

    Explained as temporary due to manufacturing overhead leverage and milestone timing

  • SG&A expense increase

    low

    SG&A increased 22% YoY for full year primarily driven by NRT acquisition and commercial activities

    Justified by strategic acquisitions and commercial investments

  • Asset impairment charges

    low

    Impairment of ₹169 crores for full year related to certain product intangibles due to adverse market conditions

    Transparent disclosure of portfolio optimization

  • Higher effective tax rate

    low

    Full year ETR at 25.4% higher than previous year due to deferred tax adjustments

    Explained as one-time adjustments related to prior periods

Q&A highlights

3 direct
Strategic acquisition integration Direct
These results include contributions from the acquired consumer healthcare business in Nicotine Replacement Therapy (NRT), which added ₹597 crores in Q4 and ₹1,202 crores for the full year

Successful integration of strategic acquisition contributing significantly to growth

Asked by Various

Record financial milestones Direct
We achieved record-high revenues exceeding $3.8 billion and crossed the $1 billion threshold in EBITDA for the first time

Company achieved significant financial milestones demonstrating scale and profitability

Asked by Management remarks

R&D investment strategy Direct
R&D remains a key pillar for long-term growth. We continue to enhance our internal R&D efforts, with strategic external collaborations

Continued commitment to innovation and pipeline development

Asked by Management remarks

1 min read 5 chapters

Detailed narrative

Record-Breaking Financial Performance

Dr. Reddy's achieved several significant milestones in FY25, with record revenues exceeding $3.8 billion and EBITDA crossing $1 billion for the first time in company history. The Q4 performance was particularly strong with 20% revenue growth and 32% EBITDA growth, demonstrating the company's operational leverage and strategic execution capabilities.

Strategic Acquisition Success

The acquisition of the consumer healthcare business in Nicotine Replacement Therapy (NRT) proved highly successful, contributing ₹1,202 crores to full-year revenues. This strategic move not only added to the top line but also diversified the company's portfolio into the consumer healthcare segment, providing new growth avenues.

Robust R&D Investment and Innovation Focus

The company maintained its commitment to innovation with R&D investment of ₹2,738 crores for the full year, representing a 20% increase. The focus on building a differentiated pipeline spanning small molecules, biosimilars, complex generics, peptides, and novel oncology assets positions the company well for future growth.

Operational Excellence and Margin Management

Despite some Q4 margin pressure, the company maintained stable full-year gross margins at 58.5%. The temporary margin decline was attributed to manufacturing overhead leverage issues and milestone timing differences, indicating operational factors rather than fundamental challenges.

Strong Cash Generation and Financial Health

The company demonstrated strong profitability with PBT of ₹2,005 crores in Q4, representing 25% growth. Higher finance income from foreign exchange gains and disciplined cost management supported overall financial performance. The achievement of billion-dollar EBITDA threshold demonstrates the company's scale and operational efficiency.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls